01931 IVD MEDICAL
- 1.590
- 0.0000.00%
IVD MEDICAL News
Huajian Healthcare (01931) will pay a final dividend of HK$0.06209 per share on July 25
Huajian Healthcare (01931) issued an announcement that will be distributed on July 25, 2024 until December 3, 2023...
IVD MEDICAL To Go Ex-Dividend On July 15th, 2024 With 0.06209 HKD Dividend Per Share
April 30th - $IVD MEDICAL(01931.HK)$ is trading ex-dividend on July 15th, 2024. Shareholders of record on July 16th, 2024 will receive 0.06209 HKD dividend per share on July 25th, 2024. The ex-div
華檢醫療：變更股東週年大會日期、記錄日期、暫停登記期及股息派付日期
IVD MEDICAL: Annual Report 2023
Huajian Healthcare (01931): Chen Shauji and Law Jianhui appointed as executive directors
Huajian Medical (01931) issued an announcement. Since March 28, 2024, Liu Shaoji has resigned as an independent non-executive director...
Featured announcements | Fuyao Glass's net profit in 2023 increased 18.37% year on year; passenger occupancy rates of the three major airlines all recovered to more than 80% in February
Meitu's adjusted net profit in 2023 was about 370 million yuan, up 233.2% year on year; Longhu Group's total contract sales amount for February was 5.75 billion yuan.
Huajian Healthcare (01931) will pay a final dividend of HK$0.06209 per share on May 29
Huajian Medical (01931) issued an announcement that it will be distributed on May 29, 2024 until December 3, 2023...
Profit attributable to owners of Huajian Healthcare (01931.HK)'s 2023 parent company increased 13.4% year-on-year
Gelonghui, March 15, 丨 Huajian Medical (01931.HK) announced that for the year ended December 31, 2023, the Group recorded revenue of RMB 3,089 billion, an increase of 12.4% over the same period in 2022. Profit attributable to owners of parent companies was RMB 238 million, an increase of 13.4% over the same period in 2022. The increase in revenue is mainly due to increased demand for IVD products from end customers, which is due to the gradual return of hospital operations to normal after COVID-19. The increase in profit during the year was mainly due to (i) increased earnings; and (ii) share award schemes
IVD MEDICAL: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Huajian Healthcare (01931): Liu Fei appointed as non-executive director
Huajian Healthcare (01931) issued an announcement. Yang Zhaoxu resigned as a non-executive director due to his retirement, and Liu Fei was appointed as a non-executive director...
Huajian Healthcare (01931.HK) will hold a board meeting on March 15 to approve the annual results
Gelonghui March 5 | Huajian Healthcare (01931.HK) announced that the company will hold a board meeting on March 15, 2024 to consider and approve the Group's annual results for the year ended December 31, 2023, pay a final dividend (if any), and handle any other matters.
Morgan Stanley sold 92.6467 million shares of common shares of Huajian Healthcare (01931.HK) off the market, worth approximately HK$157 million
On February 2, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on February 2, Morgan Stanley (Morgan Stanley) sold $92.6467 million common shares worth about HK$157 million off the market at an average price of HK$1.7 million per share on January 30. After the sale, the latest number of shares held by Morgan Stanley was 342,000 shares, and the good position ratio dropped from 6.86% to 0.02%. Additional information: Morgan Stanley completed sale of the shares
Huajian Healthcare (01931.HK): Sun Tao resigns as non-executive director
Gelonghui January 31 | Huajian Medical (01931.HK) announced that the company has received Sun Tao's proposal to resign as a non-executive director due to his work adjustments, effective January 30, 2024.
Selected Announcements | Tencent made large repurchases for 3 consecutive days, totaling over HK$3 billion; Yuexiu Real Estate spent about 4.4 billion yuan to acquire land in Tianhe, Guangzhou
Clover Biotech announced positive data from a phase I clinical trial of SCB-219M, a targeted drug for tumor chemotherapy-related thrombocytopenia (CIT); Fu Hong Hanlin: Hansform® was approved for marketing in Indonesia to treat widespread small cell lung cancer.
The strategic cooperation agreement signed between Huajian Medical (01931.HK) and Heeson Meikang Shanghai on a strategic cooperation in the blood coagulation products business has been completed
Gelonghui, December 28, 丨 Huajian Healthcare (01931.HK) announced that on December 28, 2023, the strategic cooperation agreement signed between Weishida, a wholly-owned subsidiary of the company, and Heathson Meikang Shanghai on strategic cooperation in the blood coagulation products business has been completed. The strategic cooperation will strengthen the relationship between the two parties. Under normal circumstances, it is possible to effectively maintain the supply of Heathson Macron products distributed by Wisdom and maintain the regions where Westar is authorized to distribute. The strategic cooperation will also enable the two sides to utilize their respective strengths, resources and expertise to continue to develop a long-term and mutually beneficial strategic relationship with the Group.
IVD Medical Unit Hired as Distributor by Controlling Shareholder for One Year
IVD Medical Holding (HKG:1931) unit Vastec Medical Equipment (Shanghai) has agreed to act as a distributor for certain products of controlling shareholder Shinva Medical Instrument in Mainland China f
Sysmex Unit Plans to Acquire Shares in IVD Medical's Subsidiary
Sysmex's (TYO:6869) unit, Sysmex Shanghai, plans to inject capital to and become a shareholder of IVD Medical Holding's (HKG:1931) subsidiary, Vastec Medical Equipment (Shanghai), as part of a coopera
Selected announcements | Cinda Biotech's Q3 product revenue increased 45% year on year; Jiumaojiu plans to repurchase no more than HK$150 million in shares
Auto Home: Total net revenue for Q3 in 2023 was 1,906 billion yuan, an increase of 3.42% over the previous year; Vanke Enterprises: From January to October, it achieved cumulative contract sales of 312.44 billion yuan.
IVD MEDICAL: Interim Report 2023
IVD MEDICAL To Go Ex-Dividend On September 4th, 2023 With 0.0297 HKD Dividend Per Share
August 22nd - $IVD MEDICAL(01931.HK)$ is trading ex-dividend on September 4th, 2023. Shareholders of record on September 5th, 2023 will receive 0.0297 HKD dividend per share on September 13th, 202
Analysis
Price Target
No Data
